Federal government reviewing new vaccine thought to be effective against COVID-19 variants
The federal government is reviewing a new COVID-19 vaccine that has been submitted for regulatory approval.
Maryland-based Novavax quietly applied on Friday for Health Canada to approve its vaccine, which studies have suggested is effective against the British and South African variants of the virus.
The application comes less than two weeks after Ottawa finalized an agreement with the company for 52 million doses of the vaccine, with an option to purchase another 24 million.
The regulatory review also comes as Ottawa continues pressing the European Union on new controls on the export of vaccines from the continent.
International Trade Minister Mary Ng spoke to her European counterpart for the second time in three days on Saturday as part of a broader effort to ensure vaccines bound for Canada will not be affected.
The EU's new export controls come amid reduced shipments of the Pfizer-BioNTech vaccine because of a temporary shutdown of its plant in Belgium.
- Canada’s vaccine deliveries further threatened as Europe mulls export controls
- First doses of Pfizer COVID-19 vaccine, not yet approved, to land in Canada next week
- Canada signs deal with Novovax to get 76 million doses of COVID-19 vaccine
- Health Canada to announce approval of Johnson and Johnson vaccine against COVID-19
- Health Canada approves AstraZeneca’s COVID-19 vaccine
- Mississauga men celebrating big lotto wins as the machine froze
- BREAKING: Mississauga and Brampton to enter the grey/lockdown zone of the province’s COVID-19 framework
- Here’s what Mississauga residents can and cannot do under grey lockdown restrictions
- Here’s where restaurants in Mississauga do their shopping – Mississauga’s Largest Cash and Carry
- Hamilton Police release photo of suspects accused of killing Tyler Pratt in Stoney Creek